Marshall Wace’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-29,030
| Closed | -$170K | – | 3469 |
|
|
2022
Q4 | $170K | Buy |
+29,030
| New | +$153K | ﹤0.01% | 2720 |
|
|
2022
Q3 | – | Sell |
-89,146
| Closed | -$374K | – | 3972 |
|
|
2022
Q2 | $374K | Buy |
+89,146
| New | +$353K | ﹤0.01% | 2935 |
|
|
2022
Q1 | – | Sell |
-45,383
| Closed | -$143K | – | 4296 |
|
|
2021
Q4 | $143K | Sell |
45,383
-29,570
| -39% | -$98.4K | ﹤0.01% | 3277 |
|
|
2021
Q3 | $245K | Buy |
74,953
+54,498
| +266% | +$191K | ﹤0.01% | 2725 |
|
|
2021
Q2 | $86K | Sell |
20,455
-32,226
| -61% | -$136K | ﹤0.01% | 2548 |
|
|
2021
Q1 | $263K | Buy |
52,681
+33,216
| +171% | +$268K | ﹤0.01% | 2166 |
|
|
2020
Q4 | $246K | Buy |
+19,465
| New | +$222K | ﹤0.01% | 1703 |
|
|
2019
Q4 | – | Sell |
-3,894
| Closed | -$23K | – | 2183 |
|
|
2019
Q3 | $23K | Sell |
3,894
-98,003
| -96% | -$1.04M | ﹤0.01% | 1591 |
|
|
2019
Q2 | $1.22M | Buy |
+101,897
| New | +$1.1M | 0.01% | 882 |
|
|
2014
Q2 | – | Sell |
-60,000
| Closed | -$807K | – | 1107 |
|
|
2014
Q1 | $807K | Buy |
+60,000
| New | +$847K | 0.01% | 518 |
|
Marshall Wace's CNCE Position: Q1 2023 in Review
Marshall Wace sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 29,030 shares — an estimated $170K sold.
Marshall Wace first reported a position in CNCE in Q1 2014 and held it in 10 quarters. The position peaked at $1.22M in Q2 2019. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Marshall Wace reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Marshall Wace sold 29,030 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $170K.
- Marshall Wace first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 10 quarters.
- Marshall Wace's Concert Pharmaceuticals, Inc. position peaked at $1.22M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.